HROW Latest Press Releases

-- October 5, 2026 --

Harrow Closes Acquisition of TYRVAYA Globe Newswire 7:00 AM

-- September 30, 2026 --

Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO Globe Newswire 7:00 AM

-- September 1, 2026 --

Harrow to Participate in Three Investor Conferences in September Globe Newswire 7:00 AM

-- August 20, 2026 --

Harrow Announces IHEEZO Data in Patient-Reported Discomfort Following Intravitreal Injections Globe Newswire 7:00 AM

-- August 10, 2026 --

Harrow Announces Second Quarter 2026 Financial Results Globe Newswire 4:05 PM

-- August 6, 2026 --

Harrow Acquires Global Rights to TYRVAYA, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease Globe Newswire 7:00 AM

-- July 27, 2026 --

Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026 Globe Newswire 7:00 AM

-- July 20, 2026 --

Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ / AMELIVU), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026 Globe Newswire 8:00 AM

Harrow Highlights Growing Clinical Evidence Supporting IHEEZO and BYOOVIZ at ASRS 2026 Annual Meeting Globe Newswire 7:00 AM

-- July 1, 2026 --

Harrow Announces Commercial Launch of BYOOVIZ in the United States Globe Newswire 7:00 AM

Samsung Bioepis Relaunches BYOOVIZ (ranibizumab-nuna) in the United States in Partnership with Harrow Business Wire 7:00 AM

-- June 10, 2026 --

Harrow Re-Launches VERKAZIA (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare Globe Newswire 7:00 AM

-- May 27, 2026 --

Harrow to Present at William Blair's 46th Annual Growth Stock Conference Globe Newswire 7:00 AM

Market Data Delayed 15 Minutes